Home Applications 203093 Application 203093
Type NDA
Sponsor GILEAD SCIENCES INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 VITEKTA ELVITEGRAVIR TABLET;ORAL 85MG Yes No 002 VITEKTA ELVITEGRAVIR TABLET;ORAL 150MG Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N203093-001 VITEKTA ELVITEGRAVIR 85MG TABLET / ORAL RLD 2014-09-24 N203093-002 VITEKTA ELVITEGRAVIR 150MG TABLET / ORAL RLD 2014-09-24
Orange Book patents# Current patent rows page 1 of 1 · 12 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N203093-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 N203093-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 N203093-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 N203093-001 7176220*PED 2027-02-27 Pediatric extension N203093-001 7635704*PED 2027-04-26 Pediatric extension N203093-001 8981103*PED 2027-04-26 Pediatric extension N203093-002 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 N203093-002 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 N203093-002 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 N203093-002 7176220*PED 2027-02-27 Pediatric extension N203093-002 7635704*PED 2027-04-26 Pediatric extension N203093-002 8981103*PED 2027-04-26 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 3 · 88 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2019-12-13 00:20 UTC 2019-12 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 782e0a99824c…2021-12-28 21:50 UTC 2021-12 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 87673890dc5c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 5aa47cf7b7d7…2021-03-12 10:30 UTC 2021-03 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 b00525d2431f…2019-09-15 20:21 UTC 2019-09 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 ea99ee380514…2019-07-19 19:46 UTC 2019-07 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 6a51e52b5d6a…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 1c564ffb4f44…2024-02-18 07:12 UTC 2024-02 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 ea1830bbd6c7…2023-12-20 04:57 UTC 2023-12 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 a72a2bbeb626…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 9b2671bbb829…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 a67488948f0b…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 3f0d92c62455…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 053a50430f4f…2023-05-13 08:27 UTC 2023-05 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 3bdfa0b2c4d7…2023-01-26 05:58 UTC 2023-01 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N203093-001 VITEKTA 85MG TABLET / ORAL RLD 2014-09-24 3a93d1ddd44b…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N203093-002 VITEKTA 150MG TABLET / ORAL RLD 2014-09-24 3a93d1ddd44b…
Observed Orange Book patent history# Patent history page 1 of 12 · 480 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N203093-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-001 7176220*PED 2027-02-27 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-001 7635704*PED 2027-04-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-001 8981103*PED 2027-04-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-002 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-002 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-002 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-002 7176220*PED 2027-02-27 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-002 7635704*PED 2027-04-26 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203093-002 8981103*PED 2027-04-26 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N203093-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-001 7176220*PED 2027-02-27 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-001 7635704*PED 2027-04-26 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-001 8981103*PED 2027-04-26 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-002 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-002 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-002 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-002 7176220*PED 2027-02-27 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-002 7635704*PED 2027-04-26 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203093-002 8981103*PED 2027-04-26 Pediatric extension 84e616aacf4f…2026-08-18 06:07:40 2026-07 N203093-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-001 7176220*PED 2027-02-27 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-001 7635704*PED 2027-04-26 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-001 8981103*PED 2027-04-26 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-002 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-002 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-002 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-002 7176220*PED 2027-02-27 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-002 7635704*PED 2027-04-26 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203093-002 8981103*PED 2027-04-26 Pediatric extension caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N203093-001 7176220 2026-08-27 U-257 Drug substance, Drug product 2014-10-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203093-001 7635704 2026-10-26 U-257 Drug substance, Drug product 2014-10-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203093-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203093-001 7176220*PED 2027-02-27 Pediatric extension 011fe1cb6892…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 43420 ORIG 2016-03-28 40257 SUPPL 2015-07-30 10155 SUPPL 2015-07-28 19418 ORIG 2014-09-26 10154 ORIG 2014-09-26